368 related articles for article (PubMed ID: 26811671)
1. Pasireotide: a novel treatment for patients with acromegaly.
Cuevas-Ramos D; Fleseriu M
Drug Des Devel Ther; 2016; 10():227-39. PubMed ID: 26811671
[TBL] [Abstract][Full Text] [Related]
2. The Effect of 6 Months' Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings.
Witek P; Bolanowski M; Szamotulska K; Wojciechowska-Luźniak A; Jawiarczyk-Przybyłowska A; Kałużny M
Front Endocrinol (Lausanne); 2021; 12():633944. PubMed ID: 33776927
[TBL] [Abstract][Full Text] [Related]
3. How to Position Pasireotide LAR Treatment in Acromegaly.
Coopmans EC; Muhammad A; van der Lely AJ; Janssen JAMJL; Neggers SJCMM
J Clin Endocrinol Metab; 2019 Jun; 104(6):1978-1988. PubMed ID: 30608534
[TBL] [Abstract][Full Text] [Related]
4. Pasireotide in Acromegaly: A Review.
McKeage K
Drugs; 2015 Jun; 75(9):1039-48. PubMed ID: 26017304
[TBL] [Abstract][Full Text] [Related]
5. Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR.
Samson SL
Drugs; 2016 Sep; 76(13):1235-1243. PubMed ID: 27473537
[TBL] [Abstract][Full Text] [Related]
6. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
[TBL] [Abstract][Full Text] [Related]
7. Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response.
Chiloiro S; Giampietro A; Mirra F; Donfrancesco F; Tartaglione T; Mattogno PP; Angelini F; Liverana L; Gessi M; Carmelo A; Rindi G; Giustina A; Fleseriu M; Pontecorvi A; De Marinis L; Bianchi A
Eur J Endocrinol; 2021 Feb; 184(2):217-229. PubMed ID: 33136550
[TBL] [Abstract][Full Text] [Related]
8. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.
Colao A; Bronstein MD; Freda P; Gu F; Shen CC; Gadelha M; Fleseriu M; van der Lely AJ; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Sheppard M;
J Clin Endocrinol Metab; 2014 Mar; 99(3):791-9. PubMed ID: 24423324
[TBL] [Abstract][Full Text] [Related]
9. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
Bronstein MD; Fleseriu M; Neggers S; Colao A; Sheppard M; Gu F; Shen CC; Gadelha M; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Freda P;
BMC Endocr Disord; 2016 Apr; 16():16. PubMed ID: 27039081
[TBL] [Abstract][Full Text] [Related]
10. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.
Sheppard M; Bronstein MD; Freda P; Serri O; De Marinis L; Naves L; Rozhinskaya L; Hermosillo Reséndiz K; Ruffin M; Chen Y; Colao A
Pituitary; 2015 Jun; 18(3):385-94. PubMed ID: 25103549
[TBL] [Abstract][Full Text] [Related]
11. Pasireotide in Acromegaly: An Overview of Current Mechanistic and Clinical Data.
Samson SL
Neuroendocrinology; 2015; 102(1-2):8-17. PubMed ID: 25792118
[TBL] [Abstract][Full Text] [Related]
12. Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation.
Stelmachowska-Banaś M; Czajka-Oraniec I; Tomasik A; Zgliczyński W
Pituitary; 2022 Feb; 25(1):180-190. PubMed ID: 34498217
[TBL] [Abstract][Full Text] [Related]
13. T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly.
Coopmans EC; Schneiders JJ; El-Sayed N; Erler NS; Hofland LJ; van der Lely AJ; Petrossians P; Potorac J; Muhammad A; Neggers SJCMM
Eur J Endocrinol; 2020 Jun; 182(6):595-605. PubMed ID: 32375119
[TBL] [Abstract][Full Text] [Related]
14. Pasireotide: potential treatment option for McCune-Albright-associated acromegaly.
Ilie MD; Raverot G; Brac de la Perrière A
Eur J Endocrinol; 2024 Jan; 190(1):K17-K20. PubMed ID: 38128124
[TBL] [Abstract][Full Text] [Related]
15. Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly.
Chang JS; Tseng HM; Chang TC
J Formos Med Assoc; 2016 Jun; 115(6):475-80. PubMed ID: 27117887
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological management of acromegaly: a current perspective.
Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of switching to Pasireotide in Acromegaly Patients controlled with Pegvisomant and Somatostatin Analogues: PAPE extension study.
Muhammad A; Coopmans EC; Delhanty PJD; Dallenga AHG; Haitsma IK; Janssen JAMJL; van der Lely AJ; Neggers SJCMM
Eur J Endocrinol; 2018 Oct; 179(5):269-277. PubMed ID: 30076159
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapy for acromegaly: future role for pasireotide?
Ben-Shlomo A
Endocrinol Metab Clin North Am; 2015 Mar; 44(1):35-41. PubMed ID: 25732640
[TBL] [Abstract][Full Text] [Related]
19. De-escalation treatment with pasireotide for acromegaly: a long-term experience.
Giampietro A; Menotti S; Chiloiro S; Pontecorvi A; De Marinis L; Bianchi A
Endocrine; 2023 Jun; 80(3):505-510. PubMed ID: 36808072
[TBL] [Abstract][Full Text] [Related]
20. Pasireotide in the Personalized Treatment of Acromegaly.
Puig-Domingo M; Bernabéu I; Picó A; Biagetti B; Gil J; Alvarez-Escolá C; Jordà M; Marques-Pamies M; Soldevila B; Gálvez MA; Cámara R; Aller J; Lamas C; Marazuela M
Front Endocrinol (Lausanne); 2021; 12():648411. PubMed ID: 33796079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]